Cms-10434 #26 Aqm2018-ssa Ad

Centers for Medicare & Medicaid
Services
CMS eXpedited Life Cycle (XLC)

Medicaid and CHIP Program (MACPro)
AQM 2018 - Adherence to Antipsychotic
Medications for Individuals with Schizophrenia
(SAA-AD) Core Measure PRA document
Version 1.0
07/02/2018

Document Number: 467-AQM 2018-SSA-AD-PRA-D
Contract Number: HHSM-500-2007-00024I: HHSM-500-T0014

CMS XLC

Table of Contents

Table of Contents
1. Adherence to Antipsychotics for Individuals with Schizophrenia (SAA-AD)
Core Measure –Screenshots ................................................................................... 1
1.1
1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
1.10
1.11
1.12

Are you reporting on this measure? ................................................................ 1
Measurement Specification – Path 1 ............................................................... 1
Measurement Specification – Path 2 ............................................................... 1
Data Source .................................................................................................... 2
Date Range ..................................................................................................... 2
Definition of Population Included in the Measure ............................................ 3
Performance Measure ..................................................................................... 3
Deviations from Measurement Specifications ................................................. 4
Combined Rate(s) from Multiple Reporting Units ............................................ 4
Additional Notes/Comments on Measure (Optional) ....................................... 4
Optional Measure Stratification – Screenshot 1 .............................................. 5
Optional Measure Stratification – Screenshot 2 .............................................. 5

Appendix A:

Acronyms ......................................................................................... 6

List of Figures
Figure 1: Are you reporting on this measure? ................................................................. 1
Figure 2: Measurement Specification – 1 ........................................................................ 1
Figure 3: Measurement Specification – 2 ........................................................................ 1
Figure 4: Data Source ..................................................................................................... 2
Figure 5: Date Range ...................................................................................................... 2
Figure 6: Definition of Population Included in the Measure ............................................. 3
Figure 7: Performance Measure ...................................................................................... 3
Figure 8: Deviations from Measurement Specifications .................................................. 4
Figure 9: Combined Rate(s) from Multiple Reporting Units ............................................. 4
Figure 10: Additional Notes/Comments on Measure (Optional) ...................................... 4
Figure 11: Optional Measure Stratification – 1 ................................................................ 5
Figure 12: Optional Measure Stratification – 2 ................................................................ 5

AQM 2018 - Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA-AD) Core Measure PRA document
Version 1.0
i

07/02/2018

CMS XLC

List of Tables

List of Tables
Table 1: Acronyms .......................................................................................................... 6

AQM 2018 - Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA-AD) Core Measure PRA document
Version 1.0
ii

07/02/2018

CMS XLC

Adherence to Antipsychotics for Individuals with Schizophrenia (SAA-AD) Core Measure –Screenshots

1. Adherence to Antipsychotics for Individuals with
Schizophrenia (SAA-AD) Core Measure –
Screenshots
1.1

Are you reporting on this measure?

Figure 1: Are you reporting on this measure?

1.2

Measurement Specification – Path 1

Figure 2: Measurement Specification – 1

1.3

Measurement Specification – Path 2

Figure 3: Measurement Specification – 2

AQM 2018 - Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA-AD) Core Measure PRA document
Version 1.0
1

07/02/2018

CMS XLC

1.4

Adherence to Antipsychotics for Individuals with Schizophrenia (SAA-AD) Core Measure –Screenshots

Data Source

Figure 4: Data Source

1.5

Date Range

Figure 5: Date Range

AQM 2018 - Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA-AD) Core Measure PRA document
Version 1.0
2

07/02/2018

CMS XLC

1.6

Adherence to Antipsychotics for Individuals with Schizophrenia (SAA-AD) Core Measure –Screenshots

Definition of Population Included in the Measure

Figure 6: Definition of Population Included in the Measure

1.7

Performance Measure

Figure 7: Performance Measure

AQM 2018 - Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA-AD) Core Measure PRA document
Version 1.0
3

07/02/2018

CMS XLC

1.8

Adherence to Antipsychotics for Individuals with Schizophrenia (SAA-AD) Core Measure –Screenshots

Deviations from Measurement Specifications

Figure 8: Deviations from Measurement Specifications

1.9

Combined Rate(s) from Multiple Reporting Units

Figure 9: Combined Rate(s) from Multiple Reporting Units

1.10 Additional Notes/Comments on Measure (Optional)

Figure 10: Additional Notes/Comments on Measure (Optional)

AQM 2018 - Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA-AD) Core Measure PRA document
Version 1.0
4

07/02/2018

CMS XLC

Adherence to Antipsychotics for Individuals with Schizophrenia (SAA-AD) Core Measure –Screenshots

1.11 Optional Measure Stratification – Screenshot 1

Figure 11: Optional Measure Stratification – 1

1.12 Optional Measure Stratification – Screenshot 2
Note: Same N/D/R sets are displayed under each of the stratification categories

Figure 12: Optional Measure Stratification – 2

AQM 2018 - Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA-AD) Core Measure PRA document
Version 1.0
5

07/02/2018

CMS XLC

Adherence to Antipsychotics for Individuals with Schizophrenia (SAA-AD) Core Measure –Screenshots

Appendix A: Acronyms
Table 1: Acronyms
Acronym

Literal Translation

AQM

Adult Quality Measure

PRA

Paper Reduction Act of 1995

AQM 2018 - Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA-AD) Core Measure PRA document
Version 1.0
6

07/02/2018